Skip to main content

Pipeline

Product Candidate
Discovery
PRECLIN
PHASE 1
PHASE 2
PHASE 3
MARKET
Status
HCVProtease Inhibitor
glecaprevir-containing combo* (MAVYRET™)
Pan-genotypic: Marketed by AbbVie
HCVProtease Inhibitor
paritaprevir-containing regimens
GT1 and GT4: Marketed outside the U.S. by AbbVie
NASHFXR Agonist
EDP-305
Phase 2 "ARGON-1" study
PBCFXR Agonist
EDP-305
Phase 2 "INTREPID" study
RSVN-protein Inhibitor
EDP-938
Phase 1
HBVCore Inhibitor
Preclinical
NASHFXR Agonist follow-on
Preclinical
NASHUndisclosed
Preclinical

*Fixed-dose combination, formerly known as G/P, contains glecaprevir and AbbVie's NS5A Inhibitor, pibrentasvir